Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918357 · ClinicalTrials.gov registry record · Phase 2
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT02918357: Completed Phase 2 study, sponsored by University of California, San Francisco.
NCT02918357 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 385 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (189% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02918357, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.
Primary Outcome
PPVs were calculated across the group on a per-patient basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% confidence intervals (CI). The CIs were constructed using the Wilson score method.
Interventions
- DRUG Ga-68 labeled PSMA-11 PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2017-09-21 |
| Phase | Phase 2 |
What the finished NCT02918357 record still lists
NCT02918357 is an interventional study that assigns participants to a tested intervention. The registered 385 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (189% higher).
The record links to 0 conditions, and to 1 intervention - of which Ga-68 labeled PSMA-11 PET is the first listed.
NCT02918357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02918357 about?
NCT02918357 is a clinical study titled "Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence". The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.
What is the current status of trial NCT02918357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2016-09-15. Estimated completion is 2017-09-21.
What interventions are being tested in trial NCT02918357?
The interventions under investigation include: Ga-68 labeled PSMA-11 PET (DRUG).
Who is sponsoring clinical trial NCT02918357?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02918357's enrollment target sits among peer trials
385 109th of 2000 higher than 1,890 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373823 · 385 participants · NA
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
- NCT05503173 · 385 participants · NA
Telehealth for Pain and Unhealthy Drinking Among PLWH
- NCT06226883 · 385 participants · Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- NCT06290063 · 385 participants · Phase 2
Cannabidiol and Older Adult Cannabis Users
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI